Intercell AG

Intercell AG: Announcement according to section 93 subsection 1 and 2 of the Austrian Stock Markets Act

@@start.t1@@--------------------------------------------------------------------------------   ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for   the content of this announcement. --------------------------------------------------------------------------------@@end@@

shares

Wien (euro adhoc) - Vienna (Austria), September 28, 2007 - Following the completion of a capital increase of 4.8 million shares, which were sold to Novartis Pharma AG at an issue price of EUR 31.25 per share, or EUR 150 million in total, and admission of the new shares for trading on the Official Market of the Vienna Stock Exchange, Intercell AG, with its principal offices in Vienna, makes the following required announcement about changes in the allocation of voting rights:

Announcement of Novartis´ share in voting rights according to section 93 subsection 2 of the Austrian Stock Exchange Act:

Novartis AG has informed us that entities affiliated with Novartis AG now hold 7,244,940 shares, representing 15.9 percent of the voting rights in Intercell AG, subdivided into 4,800,000 shares (10.5%) for Novartis Pharma AG, 2,400,000 shares (5.3%) for Novartis Vaccines and Diagnostics, Inc. and 44,940 shares (0.1%) for Novartis Vaccines and Diagnostics GmbH & Co. KG.

Announcement of the total number of voting rights according to section 93 subsection 1 of the Austrian Stock Markets Act:

The total number of shares of common stock with no par value of Intercell AG, each representing one vote, has increased to 45,521,707. The share capital is now EUR 45,521,707.-.

The Management Board

@@start.t2@@end of announcement                                                 euro adhoc 28.09.2007 07:25:54
--------------------------------------------------------------------------------@@end@@

ots Originaltext: Intercell AG
Im Internet recherchierbar: http://www.presseportal.ch

Further inquiry note:
Intercell AG
Mag. Dott. Astrid Meinl
Corporate Communications Manager
Tel. +43 1 20620-313
ameinl@intercell.com

Branche: Biotechnology
ISIN:      AT0000612601
WKN:        A0D8HW
Börsen:  Wiener Börse AG / official market



Weitere Meldungen: Intercell AG

Das könnte Sie auch interessieren: